Glenmark begins phase-II trial of Oglemilast for asthma
Friday, October 10, 2008 13:45 IST Our Bureau, Mumbai
Glenmark Pharmaceuticals Ltd (India) [Glenmark] has announced that a phase-II study for its lead molecule Oglemilast (GRC 3886) for the treatment of asthma has been initiated.